Status:
COMPLETED
Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Novo Nordisk A/S
Conditions:
GVHD, Chronic
Hematological Malignancy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A two sited feasibility study to test the feasibility of systematic symptom identification with disease specific and clinically developed PROM (Lee Symptom Scale) longitudinally with a 12 month follow...
Detailed Description
A prospective, non-randomized, feasibility study examining a systematic approach to symptom management using PROMs with 12 months of follow up in hematological outpatient clinic
Eligibility Criteria
Inclusion
- Adults \> 18 years old
- Approximately 3 months post HSCT (they will be included before HSCT, but the intervention will begin at 3 moths).
- Patients included needs to be able to manage a computer to receive and respond to collect PRO data.
Exclusion
- Patients who do not understand, read and speak Danish and/or have cognitive/psychiatric disorders not compatible with inclusion in a clinical study.
Key Trial Info
Start Date :
April 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04884204
Start Date
April 30 2021
End Date
July 1 2023
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100